



# TITAN BIOTECH LTD.

AN ISO 9001:2008 CERTIFIED COMPANY



Corp.Off. : 303-305 Lusa Tower, Azadpur Comm. Complex, Delhi-33, India

Ph.: 011-47020100, 27677960, 27675668, 27674615 | Fax: +91-11-47619811 | CIN: L74999RJ1992PLC013387

30.05.2016

Bombay Stock Exchange Limited  
Corporate Services Department,  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai

Dear Sir,

Sub: Intimation of Audited Financial Results for year ended 31.03.2016, quarterly results for last quarter, Audit Report, recommendation of dividend in Board Meeting held on 30<sup>th</sup> May, 2016

We are enclosing herewith following Intimations required under SEBI (Listing Obligations and Disclosure Requirement) Regulations:-

1. Audited Financial Results for the year ended 31<sup>st</sup> March, 2016 in prescribed format.
2. Audited Financial Results for the quarter ended 31<sup>st</sup> March, 2016 in prescribed format.
3. Audit Report on Financial Results as per Sr. No. 1 and Sr. No.2.
4. Declaration that the Audited Financial Results are with unmodified opinion.
5. Recommendation of Dividend of Rs. 0.75 paise per share by Board of Directors. Payment of Dividend and Book Closure to be intimated after decision on the date of AGM on a later date.
6. Statement showing particulars of Dividend in prescribed format.

You are requested to take the above intimation and information on record.

Yours Sincerely,  
For Titan Biotech Limited

*Charanjit Singh*  
Charanjit Singh  
Company Secretary

Encl. as above

R.O. & Works: Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: [marketing@titanbiotechltd.com](mailto:marketing@titanbiotechltd.com)

Website: [www.titanbiotechltd.com](http://www.titanbiotechltd.com) | [www.titanmedia.in](http://www.titanmedia.in)

PART I	Particulars	STANDALONE QUARTER ENDED			STANDALONE YEAR ENDED			CONSOLIDATED YEAR ENDED	
		31.03.2016 AUDITED	31.12.2015 UNAUDITED	31.03.2015 AUDITED	31.03.2016 AUDITED	31.03.2015 AUDITED	31.03.2016 AUDITED	31.03.2015 AUDITED	
1	<b>INCOME FROM OPERATION</b>								
	a) Net Sales / Income from Operation (net of Excise Duty and Sales tax)	1243.27	1151.07	1196.25	4561.28	4031.61	4577.05	4031.61	
	b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Total Income from Operation (Net)	1243.27	1151.07	1196.25	4561.28	4031.61	4577.05	4031.61	
2	<b>EXPENSES</b>								
	(a) Cost of Materials Consumed	890.17	766.34	829.15	2972.13	2653.00	2976.88	2653.00	
	(b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	(c) Changes in Inventories of finished goods, work in progress and stock in trade	-30.23	-33.05	-39.49	-40.00	-129.26	-40.00	-129.26	
	(d) Employees benefit Expenses	96.53	83.25	69.68	336.87	273.06	345.17	273.06	
	(e) Depreciation & Amortisation Expenses	19.26	19.29	29.80	76.49	83.65	77.07	83.65	
	(f) Other Expenditure ( Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	222.94	242.34	222.27	901.11	846.56	908.88	846.56	
	Total Expenses	1168.67	1078.17	1111.51	4246.60	3727.21	4268.00	3727.21	
3	Profit from Operation before Other Income, finance costs & Exceptional Items	74.60	72.90	84.74	314.68	304.40	309.05	304.40	
4	Other Income	14.39	10.74	11.62	42.74	39.84	54.79	39.84	
5	Profit from ordinary activities before Finance Costs & Exceptional Items	89.99	83.64	96.36	357.42	344.24	363.84	344.24	
6	Finance Costs	25.87	15.48	35.66	98.67	99.23	98.72	99.23	
7	Profit from Ordinary activities after Finance Costs but before Exceptional Items	63.12	68.16	60.70	258.75	245.01	265.12	245.01	
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
9	Profit/(+)/Loss(-) from ordinary activities before Tax (-)	63.12	68.16	60.70	258.75	245.01	265.12	245.01	
10	Tax Expenses								
	(a) Provision for Taxation	10.87	23.17	9.34	77.36	71.98	80.68	71.98	
	(b) Provision for Deferred Tax	2.62	2.31	9.84	8.05	9.84	10.42	9.84	
11	Net Profit (+)/Loss(-) from Ordinary Activities after tax	13.49	25.48	19.16	86.41	81.82	91.10	81.82	
12	Extraordinary Items (net of tax expense in laos)	49.63	42.68	41.52	172.34	163.19	174.02	163.19	
13	Net Profit / Loss for the period	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
14	Share of Profit/ (Loss) of associates	48.63	42.68	41.52	172.34	163.19	174.02	163.19	
15	Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
16	Net Profit / Loss after taxes, minority interest and share of profit / (loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
17	Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)	49.63	42.68	41.52	172.34	163.19	174.02	163.19	
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	773.87	773.87	773.87	773.87	773.87	773.87	773.87	
19(i)	Earning Per Share (before extraordinary items) ( of Rs. 10/- each) ( not annualised)	N.A.	N.A.	N.A.	1375.95	1273.47	1378.32	1273.47	
	(a) Basic	0.64	0.55	0.54	2.23	2.11	2.25	2.11	
	(b) Diluted	0.64	0.55	0.54	2.23	2.11	2.25	2.11	
19(ii)	Earning Per Share ( after extraordinary items) ( of Rs. 10/- each) ( not annualised)	0.64	0.55	0.54	2.23	2.11	2.25	2.11	
	(a) Basic	0.64	0.55	0.54	2.23	2.11	2.25	2.11	
	(b) Diluted	0.64	0.55	0.54	2.23	2.11	2.25	2.11	

(Rs. in Lakhs) except for EPS



PARTICULARS	STANDALONE		CONSOLIDATED	
	YEAR ENDED 31.03.2016 (Unaudited)	YEAR ENDED 31.03.2015 (Audited)	YEAR ENDED 31.03.2016 (Unaudited)	YEAR ENDED 31.03.2015 (Audited)
<b>A EQUITY AND LIABILITIES</b>				
1. Shareholders fund				
(a) Share Capital	773,870	773,870	773,870	773,870
(b) Reserve and Surplus	1375,955	1273,468	1376,217	1273,468
Sub total- Shareholders' Fund	2149,825	2047,338	2150,087	2047,338
Minority Interest	0,000		112,506	0,000
2. Non-current Liabilities				
(a) Long Term borrowings	427,593	219,491	427,593	219,491
(b) Deferred Tax Liabilities(Net)	45,374	36,327	46,750	36,327
(c) Other Long Term Liabilities	0,000	0,000	0,000	0,000
(d) Long Term Provisions	0,000	0,000	0,000	0,000
Sub total- Non Current Liabilities	472,967	255,818	474,343	255,818
3. Current Liabilities				
(a) Short Term borrowings	713,333	551,590	713,333	551,590
(b) Trade Payables	170,677	141,852	170,677	141,852
(c) Other Current Liabilities	232,785	212,162	233,965	212,162
(d) Short Term Provisions	147,213	141,832	150,535	141,832
Sub total - Current Liabilities	1264,008	1047,436	1268,510	1047,436
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>3886,800</b>	<b>3350,592</b>	<b>4005,446</b>	<b>3350,592</b>
<b>B ASSETS</b>				
1. Non Current Assets				
(a) Fixed Assets	1023,635	1082,909	1126,751	1082,909
(b) Cap. Work in progress	451,834	114,172	454,573	114,172
(c) Non Current Investments	127,494	4,994	0,000	4,994
(d) Long term Loans and Advance	44,806	22,585	44,806	22,585
(e) Other non-current assets	0,000	0,000	1,000	0,000
Sub total Non-Current Assets	1647,769	1224,660	1627,130	1224,660
2. Current Assets				
(a) Inventories	1093,826	1105,857	1098,770	1106,657
(b) Trade Receivables	574,971	641,335	591,669	641,335
(c) Cash and cash equivalents	250,651	36,008	356,417	36,008
(d) Short-Term Loan and Advances	121,597	137,494	124,061	137,494
(e) Other Current Assets	197,986	204,238	207,179	204,238
Sub total - Current Assets	2239,031	2125,932	2376,316	2125,932
<b>TOTAL ASSETS</b>	<b>3886,800</b>	<b>3350,592</b>	<b>4005,446</b>	<b>3350,592</b>

**Notes:**

- The board of Directors have approved the aforesaid result at their meeting held on 30th May 2016 after reviewed by the Audit committee of the company.
- The statutory Auditor and company have conducted Audit of these financial results in terms of regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) regulation 2015. There are no qualification in the report issued by Auditors.
- The consolidated results for the financial year ended 31st March 2016 include the results of following:-  
**SUBSIDIARY COMPANY - PEPTECH BIOSCIENCES LIMITED**
- With effect from 1st April 2015 the depreciation is calculated on the useful life of Assets.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Board of Directors at their meeting considered and recommended dividend of Rs. 0.75 per equity share of Rs. 10/- each subject to the approval of the Shareholders in General Meeting of the company.
- During the financial year, the company has acquired 53.12% equity share capital in Peptech Biosciences Ltd.
- The company has only one reportable business segment.

For and on behalf of Board  
for TITAN BIOTECH LTD.

SURESH CHAND SINGLA  
Managing Director



# DEEPIKA SETIA & CO

CHARTERED ACCOUNTANTS

Head Off. : Shop No.9, First Floor,  
Omaxe Commercial Apartment,  
Chakkan Road Baddi,  
Distt. Solan (H.P)-173205  
Ph.01795-245784

Branch Off. : 190, III Floor,  
Dr. Mukherjee Nagar, Delhi-110009  
Ph.011-27604265/5265  
E-mail ID: [deepika.setia@inbox.com](mailto:deepika.setia@inbox.com),  
[setia15@vsnl.com](mailto:setia15@vsnl.com)

## Independent Auditor's Report on Standalone & Consolidated Financial Results of M/s. Titan Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To  
The Board of Directors of M/s. TITAN BIOTECH LIMITED

We have audited the accompanying Statement of Standalone & Consolidated Financial Results of M/s. TITAN BIOTECH LIMITED ("the Holding Company"), and its Subsidiary (the Holding Company and its Subsidiary together referred to as "the Group"), for the year ended 31<sup>st</sup> March, 2016 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared on the basis of the related financial statements which is in accordance with the Accounting Standards, prescribed under section 133 of the Companies Act, 2013, as applicable and other accounting principles generally accepted in India. Our responsibility is to express an opinion on these financial results.

We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountant of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal controls relevant to the Holding Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Holding Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.



We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

In our opinion and to the best of our information and according to the explanations given to us these standalone & consolidated year to date results:

- (i) include the year to date financial results of M/s. Peptech Biosciences Limited.
- (ii) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (iii) give a true and fair view of the standalone net profit and other financial information for the quarter ended **31<sup>st</sup> March, 2016** as well as the standalone and consolidated year to date results for the period from **1<sup>st</sup> April 2015 to 31<sup>st</sup> March, 2016**.

For Deepika Setia & Co  
Chartered Accountants  
FRN-013515N



*(Handwritten signature)*

(D.S.Kajal)  
Partner  
M.No.091609

Place: Delhi

Date: 30<sup>th</sup> May 2016



# TITAN BIOTECH LTD.

AN ISO 9001:2008 CERTIFIED COMPANY



Corp.Off. : 303-305 Lusa Tower, Azadpur Comm. Complex, Delhi-33, India

Ph.: 011-47020100, 27677960, 27675668, 27674615 | Fax: +91-11-47619811 | CIN: L74999RJ1992PLC013387

## DECLARATION

We declare that the Statutory Auditors of the Company have furnished unmodified Audit Report on the Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2016.

For Titan Biotech Limited

*Charanjit Singh*

Charanjit Singh

Company Secretary

R.O. & Works: Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: [marketing@titanbiotechltd.com](mailto:marketing@titanbiotechltd.com)

Website: [www.titanbiotechltd.com](http://www.titanbiotechltd.com) | [www.titanmedia.in](http://www.titanmedia.in)



# TITAN BIOTECH LTD.

AN ISO 9001:2008 CERTIFIED COMPANY



Corp.Off. : 303-305 Lusa Tower, Azadpur Comm. Complex, Delhi-33, India

Ph.: 011-47020100, 27677960, 27675668, 27674615 | Fax: +91-11-47619811 | CIN: L74999RJ1992PLC013387

## DISCLOSURE AS PER REGULATION 43 OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATION, 2015

Name of the Company: M/s Titan Biotech Limited

Registered Office: A-902A, RIICO Industrial Area, Phase -III, Bhiwadi- 301019, Rajasthan-301019

Date of Board Meeting: 30<sup>th</sup> May, 2016

Class of Shares: Equity Share

Nominal Value: Rs. 10 each

Dividend proposed to be paid in full/ pro-rata basis for shares allotted during the year: N.A.

S.NO.	PARTICULARS	FOR THE YEAR ENDED 31 <sup>ST</sup> MARCH, 2016 (In Rs.)	FOR THE YEAR ENDED 31 <sup>ST</sup> MARCH, 2015 (In Rs.)
1	TURNOVER AND OTHER RECEIPTS	460402044	407144821
2	TOTAL EXPENDITURE	417011395	364336853
3	GROSS PROFIT BEFORE DEDUCTING ANY OF THE FOLLOWING:-	43390649	42807968
	a) INTEREST	9867177	9922872
	b) DEPRECIATION	7648804	8384641
	c) TAX LIABILITY	8640313	8181178
4	NET PROFIT AFTER TAX	17234355	16319277
	ADD: BROUGHT FORWARD FROM PREVIOUS YEAR	77346769	68013100
	ADD: TRANSFER FROM FOREIGN EXCHANGE EARNING RESERVE	0	0
5	PROFIT AVAILABLE FOR APPROPRIATION	94581124	84332377
6	PROVISION FOR INVESTMENT ALLOWANCE RESERVE	0	0

For Titan Biotech Limited.

*Charan Singh*  
Company Secretary

R.O. & Works: Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: marketing@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.titanmedia.in

7	TRANSFER TO i) GENERAL RESERVE ii) DEBENTURE REDEMPTION RESERVE iii) OTHER RESERVE	0 0 0	0 0 0
8	DIVIDEND a) PER EQUITY SHARE: RS. 0.75 PER SHARE(PREVIOUS YEAR RS. 0.75 PER SHARE) b) PER PREFERENCE SHARE: NIL c) INCOME TAX ON DIVIDEND	5804025 Nil 1181583	5804025 Nil 1181583
9	BALANCE CARRIED FORWARD	87595516	77346769
10	PARTICULARS OF PROPOSED RIGHT/BONUS ISSUE/CONVERTIBLE DEBENTURE ISSUE	Nil	Nil
11	DECISION ABOUT BUY BACK OF SHARES	Not Applicable	Not Applicable
12	CLOSURE OF REGISTER OF MEMBERS	Will be decided later and intimated accordingly	Will be decided later and intimated accordingly
13	DATE FROM WHICH DIVIDEND IS PAYABLE	Will be decided later and intimated accordingly	Will be decided later and intimated accordingly

- On May 30<sup>th</sup>, 2016 a dividend of Rs. 0.75 paise per share is recommended for declaration by the members in the AGM, the date of the AGM will be decided later.
- Above figures are based on Annual Audited financial accounts for the financial year ended 31<sup>st</sup> March, 2016.

Place: New Delhi  
Date: 30.05.2016

For Titan Biotech Limited  
Charanjit Singh  
Company Secretary  
(Company Secretary)